Objective To analyze the clinical characteristics, risk factors, diagnosis and treatment of pegylated liposomal doxorubicin (PLD)-associated intertrigo-like hand-foot syndrome on a case-by-case basis, in order to remind clinicians to pay close attention to drug safety when using PLD.Methods The clinical case of a 36-year-old female breast cancer patient with grade Ⅳ intertrigo-like hand-foot syndrome caused by doxorubicin hydrochloride liposome and complicated with infection was analyzed, and the relevant literature was summarized.Results In this case, the intertrigo-like hand-foot syndrome was probably caused by high-dose (approximately 18 mg·m^-2 per week) administration of doxorubicin hydrochloride liposome. After symptomatic support, anti-infection, delayed chemotherapy and other treatments, the patient's multiple skin lesions healed.Conclusion In the process of treatment with doxorubicin hydrochloride liposome, we should pay attention to patient education, active prevention and early identification of the disease, especially pay attention to the clinical manifestations of patients, identify the possible of PLD-associated intertrigo-like hand-foot syndrome, so as to avoid affecting the quality of life and treatment effect of patients.